Cytokinetics (CYTK) Q2 2026 earnings summary

Executive summary

• MYQORZO received FDA approval in December 2025 and launched in the US in Q1 2026, with subsequent launches in Germany, China, and regulatory progress in the UK, Netherlands, and other markets.

• Achieved strong commercial momentum for MYQORZO, with over 1,500 patients dispensed in Q2 2026 and more than 700 unique U.S. prescribers.

• Positive topline Phase 3 ACACIA-HCM results for aficamten in non-obstructive HCM met dual primary endpoints, supporting plans for a supplemental NDA submission in Q4 2026.

• Strengthened balance sheet with a $760 million public offering, ending Q2 2026 with $1.7 billion in cash, cash equivalents, and investments.

• Continued investment in a pipeline of muscle-directed investigational medicines, including omecamtiv mecarbil, ulacamten, and CK-089.

Financial highlights

• Q2 2026 total revenues were $28.6 million, down from $66.8 million in Q2 2025 due to the absence of milestone/license revenues.

• MYQORZO net product revenue reached $25.3 million (U.S.: $23M, Europe: $2.3M), driven by robust demand and initial German launch.

• R&D expenses were $97.8 million (down from $110.1M YoY); SG&A expenses rose to $104.4 million (from $65.7M YoY) due to launch costs.

• Net loss widened to $198.8 million ($1.50/share) from $134.4 million ($1.12/share) YoY.

• Cash, cash equivalents, and investments totaled $1.7 billion as of June 30, 2026.

Outlook and guidance

• Expect to submit sNDA for aficamten in nHCM in Q4 2026 and potentially receive FDA approval for MAPLE-HCM sNDA in Q4.

• Anticipate full MYQORZO launch in the UK later in 2026 and further European launches through 2027, with plans to launch in more than five additional markets by H1 2027.

• Updated 2026 GAAP R&D and SG&A expense guidance to $860M-$890M, reflecting increased commercial readiness investments.

• Management believes current cash and investments are sufficient to fund operations for at least the next 12 months.

• Ongoing enrollment in key clinical trials: COMET-HF (omecamtiv mecarbil), AMBER-HFpEF (ulacamten), and CEDAR-HCM (aficamten in pediatrics).